ONCOCROSS

  • ONCOCROSS

    • Mission

    • History

    • Leadership

    • Scientific Advisory Board

  • Technology

    • Platform

    • ONCOCROSS AI Platform

      • RAPTOR AI™

      • ONCO-RAPTOR AI™

      • ONCOfind AI™

    • in vitro / in vivo analysis

  • Collaboration

    • New Indication

    • Optimal Cancer Type Identification

    • CUP Primary Site Identification

  • News

    • Press

    • Update

  • IR

CONTACT US
한
  • ONCOCROSS

    • Mission

    • History

    • Leadership

    • Scientific Advisory Board

  • Technology

    • Platform

    • ONCOCROSS AI Platform

      • RAPTOR AI™

      • ONCO-RAPTOR AI™

      • ONCOfind AI™

    • in vitro / in vivo analysis

  • Collaboration

    • New Indication

    • Optimal Cancer Type Identification

    • CUP Primary Site Identification

  • News

    • Press

    • Update

  • IR

  • 한
  • EN
CONTACT US
  • Main
  • News
  • Press

BIOTIMES

온코크로스, 145억 원 프리 IPO 투자유치

  • 11-15-2023
https://www.biotimes.co.kr/news/articleView.html?idxno=12769
Previous
AI 신약개발 온코크로스, 코스닥 상장 도전 2년여만 재개 01-08-2024
Next
AI drug discovery platform Oncocross set for 1H24 KOSDAQ listing – CFO 11-15-2023
List

Please enter a prompt

ONCOCROSS
CEO
Yi Rang KIM / Jihoon KANG
Address
#905 7 Beobwon-ro 11-gil, Songpa-gu, Seoul, 05836, Korea
Tel
02-717-9967
Fax
02-867-9968
Email
oncocross@oncocross.com
Terms & Conditions Privacy Policy Cookie Policy
ⓒ ONCOCROSS CO., LTD. All Rights Reserved.